| abstract |
A pharmaceutical preparation for obtaining a continuous hormonal treatment for a desired period of time longer than 21-28 days, comprising a first composition containing at least one estrogen and / or at least one progestin in a predetermined amount, which is administered in the first 21-28 days, and a second composition containing at least one estrogen and / or at least one progestin, in a predetermined amount greater than the amount of the first composition, and comprising a mono or multiphase sequence of pharmaceutical dosages. Claim 9: A pharmaceutical preparation according to claim 8, characterized in that at least one estrogen is ethinyl estradiol and / or estradiol. Claim 12: A pharmaceutical preparation according to any of the preceding claims, characterized in that at least one progestin is preferably selected from the group consisting of Levonorgestrel, dienogest, signodene, drospirenone, and precursors thereof. |